Breaking News, Collaborations & Alliances

Harbour BioMed & Insilico Partner on AI-Driven Antibody Discovery

Aim to deliver innovative therapeutic solutions for the unmet medical needs of immunology, oncology, and neuroscience.

Author Image

By: Charlie Sternberg

Associate Editor

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics, and Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven biotechnology company, have entered a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence. Under the collabor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters